Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. (Q53360074)

13 May 2018

title

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. (English)

1 reference

13 May 2018

1 reference

1

1 reference

13 May 2018

author name string

S H Hamilton

2

1 reference

13 May 2018

A M Crawford

3

1 reference

13 May 2018

M A Dellva

4

1 reference

13 May 2018

G D Tollefson

5

1 reference

13 May 2018

P V Tran

6

1 reference

13 May 2018

O Blin

7

1 reference

13 May 2018

J N Beuzen

8

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 May 1997

1 reference

13 May 2018

European Neuropsychopharmacology

published in

1 reference

13 May 2018

volume

7

1 reference

13 May 2018

page(s)

125-137

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

[Effects of neuroleptics on liver function, the hematopoietic system, blood pressure and temperature regulation. Comparison of clozapine, perazine and haloperidol by evaluating medical records]

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Side effects of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Clozapine: plasma levels and prolactin response

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Clozapine in the treatment of 121 out-patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Effect of clozapine on human serum prolactin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900392-6

7 January 2021

10.1016/S0924-977X(96)00392-6

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

9169300

1 reference

13 May 2018